Could The STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Ownership Structure Tell Us Something Useful?

Every investor in STRATA Skin Sciences, Inc. (NASDAQ:SSKN) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Companies that have been privatized tend to have low insider ownership.

STRATA Skin Sciences is not a large company by global standards. It has a market capitalization of US$42m, which means it wouldn't have the attention of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions own shares in the company. Let's delve deeper into each type of owner, to discover more about STRATA Skin Sciences.

See our latest analysis for STRATA Skin Sciences

NasdaqCM:SSKN Ownership Summary June 2nd 2020
NasdaqCM:SSKN Ownership Summary June 2nd 2020
Advertisement

What Does The Institutional Ownership Tell Us About STRATA Skin Sciences?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

We can see that STRATA Skin Sciences does have institutional investors; and they hold 11% of the stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of STRATA Skin Sciences, (below). Of course, keep in mind that there are other factors to consider, too.

NasdaqCM:SSKN Income Statement June 2nd 2020
NasdaqCM:SSKN Income Statement June 2nd 2020

It looks like hedge funds own 26% of STRATA Skin Sciences shares. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Accelmed Fund is currently the largest shareholder, with 35% of shares outstanding. The second largest shareholder with 9.4%, is Nantahala Capital Management, LLC, followed by Broadfin Capital, LLC, with an ownership of 8.6%.

Our analysis suggests that the top 3 shareholders collectively control 53% of the company's shares, implying that they have considerable power to influence the company's decisions.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of STRATA Skin Sciences

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board; and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board, themselves.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own some shares in STRATA Skin Sciences, Inc.. In their own names, insiders own US$1.3m worth of stock in the US$42m company. It is good to see some investment by insiders, but I usually like to see higher insider holdings. It might be worth checking if those insiders have been buying.

General Public Ownership

With a 25% ownership, the general public have some degree of sway over SSKN. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

Private equity firms hold a 35% stake in SSKN. This suggests they can be influential in key policy decisions. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand STRATA Skin Sciences better, we need to consider many other factors. For instance, we've identified 4 warning signs for STRATA Skin Sciences that you should be aware of.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Love or hate this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Thank you for reading.

About OTCPK:SSKN

STRATA Skin Sciences

A medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America.

Slight risk with mediocre balance sheet.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1158.7% undervalued
32 users have followed this narrative
2 users have commented on this narrative
6 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.6% undervalued
48 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9220.2% undervalued
14 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$1908.3% undervalued
11 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative

Updated Narratives

AL
NOW logo
Alice3D on ServiceNow ·

NOW is an established SAAS positioned for accelerated growth over the next 5 years.

Fair Value:US$15538.4% undervalued
23 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative
EP
SVRS logo
Epstein_Research on Silver Storm Mining ·

Silver Storm Mining, oversold silver junior

Fair Value:CA$278.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ST
StoxEurope
KBC logo
StoxEurope on KBC Group ·

KBC Group (ENXTBR:KBC) Valuation Deep-Dive: Why Dividend and Book Value Models Point in Opposite Directions.

Fair Value:€116.944.9% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

IN
Investingwilly
MA logo
Investingwilly on Mastercard ·

Mastercard: The Best Dividend Stock You're Ignoring

Fair Value:US$75029.1% undervalued
100 users have followed this narrative
1 users have commented on this narrative
9 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6514.6% undervalued
69 users have followed this narrative
2 users have commented on this narrative
10 users have liked this narrative
BL
BlackGoat
CBRS logo
BlackGoat on Cerebras Systems ·

The Wafer Giant Threatening NVIDIA's GPU Hegemony

Fair Value:US$415.5449.5% undervalued
64 users have followed this narrative
3 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

ST
StoxEurope
AD logo
StoxEurope on Koninklijke Ahold Delhaize ·

I ran Ahold Delhaize through a three-model triangulation — DCF, dividend discount, and residual income — with every assumption published and tagged as fact or assumption. The interesting result isn't a number, it's a disagreement: the point estimates run from €20,03 (RIM) through €27,64 (DDM) to €64,91 (DCF), and the pairwise overlaps form two disjoint segments — €20,36–€21,54 and €39,60–€44,56. Between €21,54 and €39,60, no two of the three models agree. [img]https://staticm.fastcomments.com/1784197249786-1000x1000-ad-range-strip.png[/img] Most of the spread is lens properties rather than company drama. A dividend model structurally can't see the roughly half of shareholder returns Ahold pays through buybacks. The book is ~96 % goodwill from the 2016 merger, which pins the residual-income reading low. And ~83 % of the DCF's value sits beyond the explicit five years, so it leans hard on the terminal assumptions. Three honest lenses, three honest answers — the disagreement is the information. Disclosures Position disclosure: The author holds no position in Ahold Delhaize as at 9 July 2026. This valuation is a StoxEurope opinion, based on honest research. Mistakes are possible. This is not investment advice. Do your own research. This article demonstrates a valuation methodology. It is not an investment recommendation, is not personalised to any reader's circumstances, and every figure in it depends entirely on the stated assumptions

1
|
0